메뉴 건너뛰기
.. 내서재 .. 알림
소속 기관/학교 인증
인증하면 논문, 학술자료 등을  무료로 열람할 수 있어요.
한국대학교, 누리자동차, 시립도서관 등 나의 기관을 확인해보세요
(국내 대학 90% 이상 구독 중)
로그인 회원가입 고객센터 ENG
주제분류

추천
검색

논문 기본 정보

자료유형
학술저널
저자정보
저널정보
한국병원약사회 병원약사회지 병원약사회지 제37권 제2호
발행연도
2020.1
수록면
190 - 199 (10page)

이용수

표지
📌
연구주제
📖
연구배경
🔬
연구방법
🏆
연구결과
AI에게 요청하기
추천
검색

초록· 키워드

오류제보하기
Background : Arteriosclerosis obliterans (ASO) is a peripheral arterial obstructive disease that presents symptoms of cryesthesia (a feeling of chill in the feet and especially the toes) with walking and resting pain. However, there are no definitive treatments for ASO and there are still insufficient guidelines for the use of antiplatelet drugs which have been used for the treatment of ASO. Some studies have shown risk of bleeding from aspirin, a representative antiplatelet agent, in the Asian population. Thus, the purpose of this study was to analyze the efficacy and safety of aspirin and sarpogrelate administered for the treatment of ASO in Korea. Methods : We retrospectively reviewed the electronic medical records of adult outpatients with ASO administered aspirin or sarpogrelate at a tertiary hospital January 2012 July 2019. Patients in this study were followed up to 12 months after the start of treatment. The incidence of revascularization and the changes in low-density lipoprotein cholesterol, high-density lipoprotein cholesterol, triglyceride, total cholesterol, and glycated hemoglobin levels were compared for effect analysis. For safety analysis, we investigated the occurrence of drug-related bleeding (hematuria, hemoptysis, nose bleeding, and gastrointestinal bleeding) and drug-related adverse events (nasopharyngitis, heartburn, headache, abdominal pain, chest pain, and liver dysfunction). Results : Of 62 patients, 24 (39%) were in the aspirin group and 38 (61%) were in the sarpogrelate group. Two patients (8.3%) underwent percutaneous angioplasty within one year after aspirin administration, but none in the sarpogrelate group (p=0.15) underwent such a procedure. Drug-related bleeding occurred in three patients (7.9%) (p=0.28) and abdominal pain occurred in four patients (10.5%) (p=0.15) in the sarpogrelate group but none in the aspirin group. Conclusion : The efficacy and safety were not significantly different between aspirin and sarpogrelate treatments in patients with ASO. Further prospective studies comparing aspirin and sarpogrelate among larger population, however, are needed.

목차

등록된 정보가 없습니다.

참고문헌 (21)

참고문헌 신청

함께 읽어보면 좋을 논문

논문 유사도에 따라 DBpia 가 추천하는 논문입니다. 함께 보면 좋을 연관 논문을 확인해보세요!

이 논문의 저자 정보

최근 본 자료

전체보기

댓글(0)

0